Bleakley Financial Group LLC Invests $93,000 in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Bleakley Financial Group LLC purchased a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,108 shares of the company’s stock, valued at approximately $93,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LYEL. ProShare Advisors LLC boosted its stake in Lyell Immunopharma by 35.2% in the 1st quarter. ProShare Advisors LLC now owns 52,739 shares of the company’s stock worth $267,000 after purchasing an additional 13,726 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Lyell Immunopharma by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 518,404 shares of the company’s stock valued at $2,618,000 after purchasing an additional 54,053 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Lyell Immunopharma by 447.4% in the 1st quarter. Bank of New York Mellon Corp now owns 390,166 shares of the company’s stock worth $1,970,000 after purchasing an additional 318,890 shares in the last quarter. MetLife Investment Management LLC purchased a new position in shares of Lyell Immunopharma in the first quarter worth $427,000. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of Lyell Immunopharma during the first quarter valued at $50,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Shares of LYEL stock opened at $2.41 on Wednesday. Lyell Immunopharma, Inc. has a one year low of $1.32 and a one year high of $3.97. The company’s fifty day moving average price is $2.25 and its 200-day moving average price is $2.00. The company has a market capitalization of $612.38 million, a price-to-earnings ratio of -2.59 and a beta of -0.55.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price objective on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.